MEDP vs. CRL, INCY, LH, EXEL, NRC, PGEN, LUNA, ICLR, IQV, and FMS
Should you be buying Medpace stock or one of its competitors? The main competitors of Medpace include Charles River Laboratories International (CRL), Incyte (INCY), Laboratory Co. of America (LH), Exelixis (EXEL), National Research (NRC), Precigen (PGEN), Luna Innovations (LUNA), ICON Public (ICLR), IQVIA (IQV), and Fresenius Medical Care (FMS).
Medpace (NASDAQ:MEDP) and Charles River Laboratories International (NYSE:CRL) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
Medpace has a net margin of 15.92% compared to Charles River Laboratories International's net margin of 11.49%. Medpace's return on equity of 59.74% beat Charles River Laboratories International's return on equity.
Charles River Laboratories International received 143 more outperform votes than Medpace when rated by MarketBeat users. However, 64.00% of users gave Medpace an outperform vote while only 61.57% of users gave Charles River Laboratories International an outperform vote.
In the previous week, Medpace had 3 more articles in the media than Charles River Laboratories International. MarketBeat recorded 19 mentions for Medpace and 16 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.95 beat Medpace's score of 0.55 indicating that Charles River Laboratories International is being referred to more favorably in the news media.
78.0% of Medpace shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Charles River Laboratories International has higher revenue and earnings than Medpace. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
Medpace presently has a consensus target price of $443.00, indicating a potential upside of 12.09%. Charles River Laboratories International has a consensus target price of $253.23, indicating a potential upside of 8.36%. Given Medpace's stronger consensus rating and higher probable upside, research analysts plainly believe Medpace is more favorable than Charles River Laboratories International.
Medpace has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500.
Summary
Medpace beats Charles River Laboratories International on 11 of the 18 factors compared between the two stocks.
Get Medpace News Delivered to You Automatically
Sign up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
